Could stem cells help COVID-19 patients breathe easier?

NCT ID NCT04615429

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single dose of stem cells (mesenchymal stromal cells) could help patients with severe COVID-19 lung inflammation breathe better. Twenty adults with confirmed COVID-19 and acute respiratory distress syndrome were randomly assigned to receive either the stem cells or a placebo. The main goal was to see if oxygen levels in the blood improved within a week.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mesenchymal stromal cells (a type of stem cell)
What this could lead to
If successful, this could point toward a new treatment to improve breathing and survival in severe COVID-19 lung inflammation.
What could go wrong
This is a very small, early-phase trial with only 20 participants, so results may not apply broadly. The treatment may not improve outcomes and could cause side effects like allergic reactions or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Universitario Puerta de Hierro-Majadahonda

    Majadahonda, Madrid, 28222, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.